Sign in to view content

Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Caroline Baumal, MD, FASRS

Video
Published 2021

Related

Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Annual Meeting Talks
2019
Foveal Capillary Perfusion Density Decreases in Diabetics with DME Treated on a Fixed Regimen of Intravitreal Aflibercept Injections Over 24 Months
Brittney Statler, MD
Updates from the Field
2020
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024

Category: Diabetic Retinopathy

See more